Karyopharm to Present at 39th Annual J.P. Morgan Healthcare Conference
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced that CEO Michael Kauffman will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 4:30 p.m. ET, followed by a Q&A session at 4:50 p.m. ET. The presentation will be available via live webcast, and a replay will be archived for 30 days. Karyopharm is focused on developing innovative cancer therapies, with its lead compound, XPOVIO® (selinexor), already approved for multiple hematologic malignancies in the U.S. and under review in Europe.
- None.
- None.
NEWTON, Mass., Jan. 4, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference. The conference is being conducted in a virtual format and the presentation will take place on Monday, January 11 at 4:30 p.m. ET, followed by a question and answer breakout session at 4:50 p.m. ET.
A live webcast of the presentation and breakout session can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. A replay of the webcast will be archived on the Company's website for 30 days following the presentation.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIO® (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade® (bortezomib) and dexamethasone for the treatment of patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com.
View original content:http://www.prnewswire.com/news-releases/karyopharm-to-present-at-39th-annual-jp-morgan-healthcare-conference-301199076.html
SOURCE Karyopharm Therapeutics Inc.
FAQ
When will Karyopharm Therapeutics present at the J.P. Morgan Healthcare Conference?
Who will be presenting for Karyopharm Therapeutics at the conference?
How can I access the Karyopharm Therapeutics presentation?
What is Karyopharm Therapeutics known for?
What is the status of XPOVIO® in Europe?
